Mathematical modelling of chemotherapy combined with bevacizumab

DOI10.1515/RNAM-2017-0028zbMath1379.92020OpenAlexW2768526325MaRDI QIDQ1681955

Maxim B. Kuznetsov, Andrey V. Kolobov

Publication date: 27 November 2017

Published in: Russian Journal of Numerical Analysis and Mathematical Modelling (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1515/rnam-2017-0028

zbMATH Keywords

chemotherapyantiangiogenic therapybevacizumabtumor modelling

Mathematics Subject Classification ID

Medical applications (general) (92C50)

Related Items (4)

Transient alleviation of tumor hypoxia during first days of antiangiogenic therapy as a result of therapy-induced alterations in nutrient supply and tumor metabolism -- analysis by mathematical modeling ⋮ Analysis of anticancer efficiency of combined fractionated radiotherapy and antiangiogenic therapy via mathematical modelling ⋮ Mathematical modelling for spatial optimization of irradiation during proton radiotherapy with nanosensitizers ⋮ Investigation of solid tumor progression with account of proliferation/migration dichotomy via Darwinian mathematical model

Uses Software

• SHASTA

Cites Work

• A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
• The study of antitumor efficacy of bevacizumab antiangiogenic therapy using a mathematical model
• Flux-corrected transport. I: SHASTA, a fluid transport algorithm that works

This page was built for publication: Mathematical modelling of chemotherapy combined with bevacizumab